JP2023518340A5 - - Google Patents

Info

Publication number
JP2023518340A5
JP2023518340A5 JP2022548838A JP2022548838A JP2023518340A5 JP 2023518340 A5 JP2023518340 A5 JP 2023518340A5 JP 2022548838 A JP2022548838 A JP 2022548838A JP 2022548838 A JP2022548838 A JP 2022548838A JP 2023518340 A5 JP2023518340 A5 JP 2023518340A5
Authority
JP
Japan
Prior art keywords
combination according
combination
antigen
mrna molecules
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518340A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/053633 external-priority patent/WO2021160881A1/en
Publication of JP2023518340A publication Critical patent/JP2023518340A/ja
Publication of JP2023518340A5 publication Critical patent/JP2023518340A5/ja
Pending legal-status Critical Current

Links

JP2022548838A 2020-02-14 2021-02-15 鼻腔内mRNAワクチン Pending JP2023518340A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20157300 2020-02-14
EP20157300.3 2020-02-14
PCT/EP2021/053633 WO2021160881A1 (en) 2020-02-14 2021-02-15 Intranasal mrna vaccines

Publications (2)

Publication Number Publication Date
JP2023518340A JP2023518340A (ja) 2023-05-01
JP2023518340A5 true JP2023518340A5 (cg-RX-API-DMAC7.html) 2024-01-25

Family

ID=69593570

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548838A Pending JP2023518340A (ja) 2020-02-14 2021-02-15 鼻腔内mRNAワクチン

Country Status (13)

Country Link
US (1) US20230071518A1 (cg-RX-API-DMAC7.html)
EP (1) EP4103226A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023518340A (cg-RX-API-DMAC7.html)
KR (1) KR20230004447A (cg-RX-API-DMAC7.html)
CN (1) CN115443148B (cg-RX-API-DMAC7.html)
AU (1) AU2021219304A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015666A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170239A1 (cg-RX-API-DMAC7.html)
IL (1) IL295507A (cg-RX-API-DMAC7.html)
MX (1) MX2022009943A (cg-RX-API-DMAC7.html)
TW (1) TW202144002A (cg-RX-API-DMAC7.html)
WO (1) WO2021160881A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202209779B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11814464B2 (en) 2019-04-29 2023-11-14 Yale University Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
CA3183351A1 (en) 2020-06-19 2021-12-23 Yale University Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery
MX2023007574A (es) 2020-12-22 2023-09-29 CureVac SE "vacuna de arn contra variantes de sars-cov-2.
WO2023037320A1 (en) * 2021-09-10 2023-03-16 Intron Biotechnology, Inc. Mucosal messenger rna vaccine
WO2023108076A1 (en) * 2021-12-08 2023-06-15 Yale University Surface conjugation to poly(amine-co-ester) nanoparticles for targeting to cells and tissues
WO2024089638A1 (en) 2022-10-28 2024-05-02 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130108663A1 (en) * 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
WO2015071295A1 (en) * 2013-11-12 2015-05-21 Vrije Universiteit Brussel Rna transcription vector and uses thereof
HRP20220070T1 (hr) * 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
DE20164728T1 (de) * 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
KR20190093816A (ko) * 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
CN111971066B (zh) * 2018-01-18 2025-03-11 伊泽阿恩埃免疫疗法股份有限公司 脂质纳米颗粒

Similar Documents

Publication Publication Date Title
Akbari et al. Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia
US20230381301A1 (en) Respiratory virus nucleic acid vaccines
Sun et al. Manganese nanodepot augments host immune response against coronavirus
JP2010516290A5 (cg-RX-API-DMAC7.html)
US20230084300A1 (en) Prevention and treatment of infections including those caused by coronavirus
US20220280635A1 (en) Particles for stimulating an immune response against viral infections
JP2003518507A5 (cg-RX-API-DMAC7.html)
Tian et al. mRNA vaccines: A novel weapon to control infectious diseases
CN112552379B (zh) 合成肽在制备防治新型冠状病毒感染药物中的用途
US12409149B2 (en) Methods of targeted delivery to a host using a carrier
Mohapatra Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus
Damodharan et al. A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2
F Nahhas et al. Nanoscale pathogens treated with nanomaterial-like peptides: a platform technology appropriate for future pandemics
Duman et al. COVID-19 vaccine candidates and vaccine development platforms available worldwide
JP2022513438A5 (cg-RX-API-DMAC7.html)
Lutz et al. Advanced nanobiomedical approaches to combat coronavirus disease of 2019
CN113185586B (zh) SARS-CoV-2编码蛋白来源的T细胞表位多肽及其应用
Shah et al. SARS-COV-2
JP2023526045A5 (cg-RX-API-DMAC7.html)
Dawar et al. Current status of the coronavirus vaccination development: a review
Robertson et al. International Nonproprietary Names (INN) for novel vaccine substances: a matter of safety
López-Gómez et al. Mesoporous silicon microparticles enhance antiviral immunity and memory responses against SARS-CoV-2
CN102827248A (zh) 一种具有抗日本脑炎病毒感染的三肽及其应用
Singh et al. Current Insights on Vaccines available for COVID-19 like Flu Symptoms
RS63635B1 (sr) Parapoksvirus za kondicioniranje i lečenje koronavirusnih infekcija